From a first step into biotech cluster networking in 2000 my time involved with LBN and One Nucleus has provided me a source of many learnings about changes in myself, the members we support and the London biotech cluster generally.
Tony Jones, CEO, One Nucleus
Email: [email protected]
Topics in this article include:
EY UK DNA of the CFO - Key findings
Global IPO markets are progressing on different trajectories. Prepared companies that maintain timing flexibility are positioned to win.
In brief
Qureight’s mission is to accelerate clinical trials and ensure breakthroughs in lung and heart disease reach patients without delay. Our AI-powered data and imaging curation platform enables the analysis of clinical imaging and other healthcare data, helping our customers bring treatments to market, faster.
Stevenage, UK, 3 August 2026 - NRG Therapeutics Ltd. (“NRG”), a clinical stage neuroscience company developing novel disease-modifying therapeutics that rectify mitochondrial dysfunction in neurodegenerative diseases, is pleased to announce the appointment of Claus Sundgreen M.D. as chief medical officer (CMO), effective 1 August 2026.
About Metrion
Metrion Biosciences ('Metrion') is a UK-based, ion channel-focused Contract Research Organisation (CRO) providing high-quality in vitro preclinical drug discovery and safety profiling services. From our headquarters at Granta Park, Cambridge, we support a global customer base with ion channel drug discovery screening, cardiac safety profiling, and neuroscience assay services.
Role Summary
PrecisionLife is helping transform the delivery of healthcare by building the next generation of precision medicine solutions and Mechanostics® tests to improve disease detection, patient triage & outcomes, predict patients’ drug responses, and reduce the cost of delivering effective care.
We are seeking an AI Transformation Lead. You will be part of a dynamic and innovative environment and will become an integral part of our vision to address patients’ unmet needs while building Britain’s Biggest Biotech. You will combine your fluency in artificial intelligence (AI) tools and emerging technologies with a robust understanding of the LifeSciences business — from discovery through to clinical development to accelerate how we work across the whole business. You will be able to work in modern facilities for optimum collaboration alongside a focused and caring team.
The future of biotech fundraising may not belong to companies that pitch to the most investors. It will more likely belong to those that understand which investors are most likely to become long-term partners and how to navigate to them efficiently. In fundraising, as in medicine, precision is beating trial and error.
*Guest blog by Lab Thread. If you would like to submit a guest blog please email [email protected].